Literature DB >> 23114755

Point mutations within the fatty acid synthase type II dehydratase components HadA or HadC contribute to isoxyl resistance in Mycobacterium tuberculosis.

Laila Gannoun-Zaki1, Laeticia Alibaud, Laurent Kremer.   

Abstract

The mechanism by which the antitubercular drug isoxyl (ISO) inhibits mycolic acid biosynthesis has not yet been reported. We found that point mutations in either the HadA or HadC component of the type II fatty acid synthase (FAS-II) are associated with increased levels of resistance to ISO in Mycobacterium tuberculosis. Overexpression of the HadAB, HadBC, or HadABC heterocomplex also produced high-level resistance. These results show that the FAS-II dehydratases are involved in ISO resistance.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23114755      PMCID： PMC3535892          DOI： 10.1128/AAC.01972-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Negative regulation by Ser/Thr phosphorylation of HadAB and HadBC dehydratases from Mycobacterium tuberculosis type II fatty acid synthase system.

Authors:  Nawel Slama; Jade Leiba; Nathalie Eynard; Mamadou Daffé; Laurent Kremer; Annaïk Quémard; Virginie Molle
Journal:  Biochem Biophys Res Commun       Date:  2011-07-27       Impact factor: 3.575

2.  Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis.

Authors:  L Kremer; J D Douglas; A R Baulard; C Morehouse; M R Guy; D Alland; L G Dover; J H Lakey; W R Jacobs; P J Brennan; D E Minnikin; G S Besra
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

3.  Mutations in the essential FAS II β-hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii.

Authors:  Juan M Belardinelli; Héctor R Morbidoni
Journal:  Mol Microbiol       Date:  2012-09-19       Impact factor: 3.501

4.  The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis.

Authors:  Emmanuelle Sacco; Adrian Suarez Covarrubias; Helen M O'Hare; Paul Carroll; Nathalie Eynard; T Alwyn Jones; Tanya Parish; Mamadou Daffé; Kristina Bäckbro; Annaïk Quémard
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

5.  Identification of the dehydratase component of the mycobacterial mycolic acid-synthesizing fatty acid synthase-II complex.

Authors:  Alistair K Brown; Apoorva Bhatt; Albel Singh; Elesh Saparia; Alex F Evans; Gurdyal S Besra
Journal:  Microbiology       Date:  2007-12       Impact factor: 2.777

6.  EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.

Authors:  Lynn G Dover; Anuradha Alahari; Paul Gratraud; Jessica M Gomes; Veemal Bhowruth; Robert C Reynolds; Gurdyal S Besra; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

7.  The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes.

Authors:  Sylvain Cantaloube; Romain Veyron-Churlet; Nabila Haddache; Mamadou Daffé; Didier Zerbib
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

8.  Oleic acid biosynthesis in Plasmodium falciparum: characterization of the stearoyl-CoA desaturase and investigation as a potential therapeutic target.

Authors:  Paul Gratraud; Enlli Huws; Brie Falkard; Sophie Adjalley; David A Fidock; Laurence Berry; William R Jacobs; Mark S Baird; Henri Vial; Laurent Kremer
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

9.  Extensively drug-resistant Mycobacterium tuberculosis, India.

Authors:  Rajesh Mondal; Amita Jain
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

10.  Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria.

Authors:  Anuradha Alahari; Xavier Trivelli; Yann Guérardel; Lynn G Dover; Gurdyal S Besra; James C Sacchettini; Robert C Reynolds; Geoffrey D Coxon; Laurent Kremer
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240
View more
  9 in total

1.  Mechanisms of Resistance Associated with the Inhibition of the Dehydration Step of Type II Fatty Acid Synthase in Mycobacterium tuberculosis.

Authors:  Anna E Grzegorzewicz; Clifford Gee; Sourav Das; Jiuyu Liu; Juan Manuel Belardinelli; Victoria Jones; Michael R McNeil; Richard E Lee; Mary Jackson
Journal:  ACS Infect Dis       Date:  2019-12-11       Impact factor: 5.084

Review 2.  Gene Transfer in Mycobacterium tuberculosis: Shuttle Phasmids to Enlightenment.

Authors:  William R Jacobs
Journal:  Microbiol Spectr       Date:  2014-04

3.  Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.

Authors:  Anna E Grzegorzewicz; Joël Lelièvre; Jorge Esquivias; Bhanupriya Angala; Jiuyu Liu; Richard E Lee; Michael R McNeil; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  Noncanonical SMC protein in Mycobacterium smegmatis restricts maintenance of Mycobacterium fortuitum plasmids.

Authors:  Michael W Panas; Paras Jain; Hui Yang; Shimontini Mitra; Debasis Biswas; Alice Rebecca Wattam; Norman L Letvin; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

Review 5.  New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.

Authors:  E Jeffrey North; Mary Jackson; Richard E Lee
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Biological and Biochemical Evaluation of Isatin-Isoniazid Hybrids as Bactericidal Candidates against Mycobacterium tuberculosis.

Authors:  Matt D Johansen; Sumit Kumar; Clément Raynaud; Diana H Quan; Warwick J Britton; Philip M Hansbro; Vipan Kumar; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

7.  Molecular basis for the inhibition of β-hydroxyacyl-ACP dehydratase HadAB complex from Mycobacterium tuberculosis by flavonoid inhibitors.

Authors:  Yu Dong; Xiaodi Qiu; Neil Shaw; Yueyang Xu; Yuna Sun; Xuemei Li; Jun Li; Zihe Rao
Journal:  Protein Cell       Date:  2015-06-17       Impact factor: 14.870

8.  Covalent modification of the Mycobacterium tuberculosis FAS-II dehydratase by Isoxyl and Thiacetazone.

Authors:  Anna E Grzegorzewicz; Nathalie Eynard; Annaïk Quémard; E Jeffrey North; Alyssa Margolis; Jared J Lindenberger; Victoria Jones; Jana Korduláková; Patrick J Brennan; Richard E Lee; Donald R Ronning; Michael R McNeil; Mary Jackson
Journal:  ACS Infect Dis       Date:  2015-02-13       Impact factor: 5.084

9.  Crystallization and X-ray diffraction studies of a complete bacterial fatty-acid synthase type I.

Authors:  Mathias Enderle; Andrew McCarthy; Karthik Shivaji Paithankar; Martin Grininger
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-10-23       Impact factor: 1.056
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.